BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 24492295)

  • 41. 89Zr immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies.
    Verel I; Visser GW; Boellaard R; Stigter-van Walsum M; Snow GB; van Dongen GA
    J Nucl Med; 2003 Aug; 44(8):1271-81. PubMed ID: 12902418
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Non invasive imaging assessment of the biodistribution of GSK2849330, an ADCC and CDC optimized anti HER3 mAb, and its role in tumor macrophage recruitment in human tumor-bearing mice.
    Alsaid H; Skedzielewski T; Rambo MV; Hunsinger K; Hoang B; Fieles W; Long ER; Tunstead J; Vugts DJ; Cleveland M; Clarke N; Matheny C; Jucker BM
    PLoS One; 2017; 12(4):e0176075. PubMed ID: 28448604
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immuno-PET Imaging to Assess Target Engagement: Experience from
    Menke-van der Houven van Oordt CW; McGeoch A; Bergstrom M; McSherry I; Smith DA; Cleveland M; Al-Azzam W; Chen L; Verheul H; Hoekstra OS; Vugts DJ; Freedman I; Huisman M; Matheny C; van Dongen G; Zhang S
    J Nucl Med; 2019 Jul; 60(7):902-909. PubMed ID: 30733323
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Radiation dosimetry of 89Zr-labeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients.
    Börjesson PK; Jauw YW; de Bree R; Roos JC; Castelijns JA; Leemans CR; van Dongen GA; Boellaard R
    J Nucl Med; 2009 Nov; 50(11):1828-36. PubMed ID: 19837762
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Preclinical 89Zr Immuno-PET of High-Grade Serous Ovarian Cancer and Lymph Node Metastasis.
    Sharma SK; Sevak KK; Monette S; Carlin SD; Knight JC; Wuest FR; Sala E; Zeglis BM; Lewis JS
    J Nucl Med; 2016 May; 57(5):771-6. PubMed ID: 26837339
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Placental growth factor (PlGF)-specific uptake in tumor microenvironment of 89Zr-labeled PlGF antibody RO5323441.
    Oude Munnink TH; Tamas KR; Lub-de Hooge MN; Vedelaar SR; Timmer-Bosscha H; Walenkamp AM; Weidner KM; Herting F; Tessier J; de Vries EG
    J Nucl Med; 2013 Jun; 54(6):929-35. PubMed ID: 23625582
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Preclinical development of ZED8, an
    Ogasawara A; Kiefer JR; Gill H; Chiang E; Sriraman S; Ferl GZ; Ziai J; Bohorquez SS; Guelman S; Wang X; Yang J; Phan MM; Nguyen V; Chung S; Yu C; Tinianow J; Waaijer SJH; De Crespigny A; Marik J; Boswell CA; Zabka T; Staflin K; Williams SP
    Eur J Nucl Med Mol Imaging; 2023 Jan; 50(2):287-301. PubMed ID: 36271158
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Long-lived positron emitters zirconium-89 and iodine-124 for scouting of therapeutic radioimmunoconjugates with PET.
    Verel I; Visser GW; Boerman OC; van Eerd JE; Finn R; Boellaard R; Vosjan MJ; Stigter-van Walsum M; Snow GB; van Dongen GA
    Cancer Biother Radiopharm; 2003 Aug; 18(4):655-61. PubMed ID: 14503961
    [TBL] [Abstract][Full Text] [Related]  

  • 49. MicroPET imaging of integrin αvβ3 expressing tumors using 89Zr-RGD peptides.
    Jacobson O; Zhu L; Niu G; Weiss ID; Szajek LP; Ma Y; Sun X; Yan Y; Kiesewetter DO; Liu S; Chen X
    Mol Imaging Biol; 2011 Dec; 13(6):1224-33. PubMed ID: 21161690
    [TBL] [Abstract][Full Text] [Related]  

  • 50. What is the Best Radionuclide for Immuno-PET of Multiple Myeloma? A Comparison Study Between
    Bailly C; Gouard S; Guérard F; Chalopin B; Carlier T; Faivre-Chauvet A; Remaud-Le Saëc P; Bourgeois M; Chouin N; Rbah-Vidal L; Tripier R; Haddad F; Kraeber-Bodéré F; Bodet-Milin C; Chérel M
    Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31137758
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemia.
    Vey N; Delaunay J; Martinelli G; Fiedler W; Raffoux E; Prebet T; Gomez-Roca C; Papayannidis C; Kebenko M; Paschka P; Christen R; Guarin E; Bröske AM; Baehner M; Brewster M; Walz AC; Michielin F; Runza V; Meresse V; Recher C
    Oncotarget; 2016 May; 7(22):32532-42. PubMed ID: 27081038
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Preclinical ImmunoPET Imaging of Glioblastoma-Infiltrating Myeloid Cells Using Zirconium-89 Labeled Anti-CD11b Antibody.
    Nigam S; McCarl L; Kumar R; Edinger RS; Kurland BF; Anderson CJ; Panigrahy A; Kohanbash G; Edwards WB
    Mol Imaging Biol; 2020 Jun; 22(3):685-694. PubMed ID: 31529407
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Preclinical Pharmacokinetics and Biodistribution Studies of 89Zr-Labeled Pembrolizumab.
    England CG; Ehlerding EB; Hernandez R; Rekoske BT; Graves SA; Sun H; Liu G; McNeel DG; Barnhart TE; Cai W
    J Nucl Med; 2017 Jan; 58(1):162-168. PubMed ID: 27493273
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The tumor targeting performance of anti-CD166 Probody drug conjugate CX-2009 and its parental derivatives as monitored by
    Chomet M; Schreurs M; Nguyen M; Howng B; Villanueva R; Krimm M; Vasiljeva O; van Dongen GAMS; Vugts DJ
    Theranostics; 2020; 10(13):5815-5828. PubMed ID: 32483421
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immuno-PET Imaging of
    Li D; Cheng S; Zou S; Zhu D; Zhu T; Wang P; Zhu X
    Mol Pharm; 2018 Apr; 15(4):1674-1681. PubMed ID: 29502426
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Preclinical evaluation of ⁸⁹Zr-labeled human antitransferrin receptor monoclonal antibody as a PET probe using a pancreatic cancer mouse model.
    Sugyo A; Tsuji AB; Sudo H; Nagatsu K; Koizumi M; Ukai Y; Kurosawa G; Zhang MR; Kurosawa Y; Saga T
    Nucl Med Commun; 2015 Mar; 36(3):286-94. PubMed ID: 25460304
    [TBL] [Abstract][Full Text] [Related]  

  • 57.
    Pool M; Kol A; de Jong S; de Vries EGE; Lub-de Hooge MN; Terwisscha van Scheltinga AGT
    MAbs; 2017; 9(8):1370-1378. PubMed ID: 28873009
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [
    Zettlitz KA; Tsai WK; Knowles SM; Salazar FB; Kobayashi N; Reiter RE; Wu AM
    Mol Imaging Biol; 2020 Apr; 22(2):367-376. PubMed ID: 31209779
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Molecular Imaging and Quantitation of EphA2 Expression in Xenograft Models with 89Zr-DS-8895a.
    Burvenich IJ; Parakh S; Gan HK; Lee FT; Guo N; Rigopoulos A; Lee ST; Gong S; O'Keefe GJ; Tochon-Danguy H; Kotsuma M; Hasegawa J; Senaldi G; Scott AM
    J Nucl Med; 2016 Jun; 57(6):974-80. PubMed ID: 26940768
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tumor-Specific Zr-89 Immuno-PET Imaging in a Human Bladder Cancer Model.
    Escorcia FE; Steckler JM; Abdel-Atti D; Price EW; Carlin SD; Scholz WW; Lewis JS; Houghton JL
    Mol Imaging Biol; 2018 Oct; 20(5):808-815. PubMed ID: 29508263
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.